Physician profile
Mark C Hanson
NPI 1265483663
$999.21
in general payments reported to CMS, 2019-2025
24 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.53 · 2020: $63.78 · 2021: $41.07 · 2022: $120 · 2023: $29.57 · 2024: $178 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $88.21 | 2020-2025 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.04 | 2024-2025 | Lifevest |
| Irhythm Technologies, INC. | $70.54 | 2024 | Zio Monitor, Zio Xt Patch |
| Vital Connect, INC | $66.67 | 2022 | |
| Amgen INC. | $65.76 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $65.25 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $64.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $63.21 | 2021-2025 | Verquvo |
| Inari Medical, INC. | $51.01 | 2020 | |
| Cvrx, INC. | $50.32 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $39.78 | 2024-2025 | Opsumit, Uptravi |
| Heartflow, INC. | $37.58 | 2025 | |
| Akcea Therapeutics, INC. | $36.25 | 2019 | |
| Boston Scientific Corporation | $31.55 | 2024 | Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2023 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $28.81 | 2019 | |
| Novo Nordisk INC | $20.32 | 2024 | Ozempic |
| Ionis Pharmaceuticals, INC. | $19.86 | 2025 | Tryngolza |
| Pfizer INC. | $17.67 | 2025 | |
| Biotronik INC. | $16.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.40 | 2021 | |
| Lantheus Medical Imaging, INC. | $12.65 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $7.87 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.